BRIEF-Astrazeneca Says Enhertu Granted BTD For Breast Cancer

AstraZeneca PLC: * ASTRAZENECA PLC - ENHERTU GRANTED BTD FOR BREAST CANCER

* ASTRAZENECA - BASED ON GROUND-BREAKING DESTINY-BREAST03 RESULTS WHERE ENHERTU REDUCED RISK OF DISEASE PROGRESSION OR DEATH BY 72% VERSUS. TRASTUZUMAB EMTANSINE (T-DM1) * ASTRAZENECA - ENHERTU HAS NOW BEEN GRANTED FOUR BREAKTHROUGH THERAPY DESIGNATIONS, INCLUDING TWO IN BREAST CANCER Source text for Eikon: Further company coverage:

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)